262 related articles for article (PubMed ID: 22384020)
21. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
[TBL] [Abstract][Full Text] [Related]
22. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
23. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
24. Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R; Akram S
Tumour Biol; 2016 Apr; 37(4):5413-26. PubMed ID: 26563369
[TBL] [Abstract][Full Text] [Related]
25. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
Zhao Z; Li R; Sha S; Wang Q; Mao W; Liu T
Cancer Biol Ther; 2014 Oct; 15(10):1404-12. PubMed ID: 25046105
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
Koay DC; Zerillo C; Narayan M; Harris LN; DiGiovanna MP
Breast Cancer Res; 2010; 12(4):R62. PubMed ID: 20696059
[TBL] [Abstract][Full Text] [Related]
27. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
28. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
29. MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer.
Tian SB; Yu JC; Liu YQ; Kang WM; Ma ZQ; Ye X; Yan C
World J Gastroenterol; 2015 Aug; 21(31):9337-47. PubMed ID: 26309359
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
[TBL] [Abstract][Full Text] [Related]
31. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
[TBL] [Abstract][Full Text] [Related]
32. miR-30b suppresses the progression of breast cancer through inhibition of the PI3K/Akt signaling pathway by targeting Derlin-1.
Zhou J; Xiang AZ; Guo JF; Cui HD
Transl Cancer Res; 2019 Feb; 8(1):180-190. PubMed ID: 35116747
[TBL] [Abstract][Full Text] [Related]
33. MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-γ.
Li P; Xie XB; Chen Q; Pang GL; Luo W; Tu JC; Zheng F; Liu SM; Han L; Zhang JK; Luo XY; Zhou X
Asian Pac J Cancer Prev; 2014; 15(16):6949-54. PubMed ID: 25169552
[TBL] [Abstract][Full Text] [Related]
34. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.
Ferracin M; Bassi C; Pedriali M; Pagotto S; D'Abundo L; Zagatti B; Corrà F; Musa G; Callegari E; Lupini L; Volpato S; Querzoli P; Negrini M
Mol Cancer; 2013 Oct; 12(1):130. PubMed ID: 24165569
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
36. Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels.
Sorokin M; Ignatev K; Barbara V; Vladimirova U; Muraveva A; Suntsova M; Gaifullin N; Vorotnikov I; Kamashev D; Bondarenko A; Baranova M; Poddubskaya E; Buzdin A
Biochemistry (Mosc); 2020 Jul; 85(7):758-772. PubMed ID: 33040720
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
38. Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4.
Ma X; Dong W; Su Z; Zhao L; Miao Y; Li N; Zhou H; Jia L
Cell Death Dis; 2016 Dec; 7(12):e2561. PubMed ID: 28032858
[TBL] [Abstract][Full Text] [Related]
39. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting.
Li P; Xu T; Zhou X; Liao L; Pang G; Luo W; Han L; Zhang J; Luo X; Xie X; Zhu K
Cancer Med; 2017 Mar; 6(3):662-672. PubMed ID: 28220627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
